We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
152 result(s) found, displaying 1 to 10
-
Prescription medicine registrationActive ingredients: empagliflozin.
-
Prescription medicine registrationActive ingredients: empagliflozin, metformin hydrochloride.
-
Australian Public Assessment Report (AusPAR)Jardiance (empagliflozin) has been approved for reducing the risk of kidney disease progression in adults with chronic kidney disease.
-
Australian Public Assessment Report (AusPAR)Spevigo (spesolimab) has been approved for the treatment of generalised pustular psoriasis, a rare but severe form of psoriasis that involves flares of widespread, non-infectious, macroscopically visible pustules.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SPEVIGO spesolimab (rch) 450 mg in 7.5 mL concentrated solution for infusion vial.
-
Apr-2024Prescription medicine evaluationActive ingredient: Tenecteplase.
-
Prescription medicine registrationActive ingredients: empagliflozin.
-
Prescription medicine decision summarySpevigo (spesolimab) is approved for the treatment of flares in adult patients with generalised pustular psoriasis.
-
Prescription medicine registrationActive ingredients: spesolimab.
-
Cancellation by sponsorRequested by Boehringer Ingelheim Pty Ltd